SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets hard-to-treat brain lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has returned or not improved with prior therapy. About 26 adults will take part. The main goal is to see what side effects occur…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:40 UTC
-
New drug duo offers hope for hard-to-treat brain lymphoma
Disease control Recruiting nowThis study tests a combination of two drugs, zanubrutinib and pemetrexed, followed by zanubrutinib alone, in 15 people with relapsed or refractory central nervous system lymphoma. The goal is to see if this treatment can control the disease and how safe it is. Participants must h…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New drug may stop aggressive lymphoma from returning after treatment
Disease control Recruiting nowThis study tests whether the drug acalabrutinib can help prevent relapse in people with very high-risk large B-cell lymphoma after they receive cell therapy (stem cell transplant or CAR T-cells). The trial enrolls 24 adults aged 18-70. Researchers will check how well patients tol…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat brain cancer
Disease control Recruiting nowThis early-phase study tests an experimental cell therapy called MB-CART19.1 for people with central nervous system lymphoma (CNSL) that has returned or not responded to prior treatments. The therapy uses a patient's own immune cells, modified to target cancer, and is made on-sit…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Brain Radiation's hidden toll: new study tracks memory loss in blood cancer patients
Knowledge-focused Recruiting nowThis study follows 100 adults with blood cancers who are receiving whole brain radiation therapy. Researchers will test memory, thinking, and quality of life over time to understand the side effects of radiation on the brain. The goal is to gather information, not to test a new t…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 01, 2026 15:29 UTC